Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accounts Payables: 2012-2025

Historic Accounts Payables for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $1.9 million.

  • Enanta Pharmaceuticals' Accounts Payables fell 75.66% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 75.66%. This contributed to the annual value of $1.9 million for FY2025, which is 75.66% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Accounts Payables of $1.9 million as of Q3 2025, which was down 45.08% from $3.5 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Accounts Payables peaked at $11.8 million during Q1 2023, and registered a low of $1.2 million during Q2 2022.
  • In the last 3 years, Enanta Pharmaceuticals' Accounts Payables had a median value of $6.7 million in 2024 and averaged $6.7 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Accounts Payables slumped by 78.88% in 2022, and later surged by 537.11% in 2023.
  • Enanta Pharmaceuticals' Accounts Payables (Quarterly) stood at $7.8 million in 2021, then slumped by 44.50% to $4.4 million in 2022, then spiked by 114.29% to $9.3 million in 2023, then crashed by 49.32% to $4.7 million in 2024, then slumped by 75.66% to $1.9 million in 2025.
  • Its Accounts Payables stands at $1.9 million for Q3 2025, versus $3.5 million for Q2 2025 and $4.8 million for Q1 2025.